Responses

Download PDFPDF
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    • Oliver Distler
    • Other Contributors:
      • Jörg H.W. Distler, Yannick Allanore, Jerome Avouac, Marco Mattucci-Cerinic

    Dear Editor,

    We thank Dres Arends and Fadini and their coworkers for their interest in our article and for their comments.

    In general, the EUSTAR recommendations are guidelines for research in an evolving field. We fully agree with the statements by Dres Arends and Fadini that these recommendations should not be considered as a final and definite, but should rather be seen as a first attempt to reach conse...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    EUSTAR’s statement and recommendations on endothelial precursor cells – putting things into perspect

    Dear Editor,

    The European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) group provided recommendations for standardization of future research on endothelial progenitor cells (EPCs)[1]. We support this initiative, as the use of different protocols by different study groups in EPC research hampers substantial advancement in this field. However, we feel that some of the statements made by the EUSTAR gr...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Sharing recommendations for endothelial progenitor cell analyses

    Dear Editor,

    We appreciated the efforts by the EUSTAR committee to provide recommendations for endothelial progenitor cell (EPC) analyses. We agree that EPC methods should be uniformed, as considerable disagreement exist that is likely to limit research advancement.[1] However, the piece contains some statements that might lead to a misinterpretation of future data on EPC analyses. These aspects have been previousl...

    Show More
    Conflict of Interest:
    None declared.